Awardee OrganizationUNIVERSITY OF CALIFORNIA SANTA BARBARA
Description
Abstract Text
DESCRIPTION (provided by applicant): The Overall Objective of the proposed investigation is to elucidate the role of the interferon-inducible RNA-specific adenosine deaminase (ADAR1) in the actions that interferons (IFN) mediate on viral and host functions. The Specific Aims of our proposed continuation study of ADAR1 and double-stranded RNA editing in IFN action are as follows: (1) To further characterize the biochemical and biophysical properties of the IFN-inducible p150 ADAR1. To determine the mechanisms by which poxvirus E3L protein and adenovirus VA1 RNA antagonize ADAR1 enzymatic activity; to characterize the functional selectivity of dsRNA binding domains of ADAR1; and to determine the structural basis and functional significance of ADAR1 protein interactions and subcellular localizations in uninfected and virus-infected cells. (2) To further delineate the structure of the 5'-flanking regions of the ADAR1 gene required for IFN-inducible and basal transcriptional activity, including the Pi promoter responsible for inducible expression of transcripts encoding the p150 ADAR1 protein isoform and the Pb and Pc promoters responsible for constitutive expression of nuclear p110 ADAR1. To define the pathways leading to inducible transcriptional activation of ADAR1 expression in IFN-treated cells and in infected mice. (3) To further characterize the effect of singular stable expression of wild type and mutant forms of ADAR1 deaminase in cultured cells on virus multiplication including VA1 mutant adenovirus, E3L mutant vaccinia virus and recombinant measles virus, to generate a targeted deletion of the mouse ADAR1 inducible genomic locus, and to determine the effect of the ADAR1 p150 disruption on mouse phenotype and viral pathogenesis. The health relatedness of the proposed research stems from the likelihood that the work may contribute to a better understanding of regulatory mechanisms operative in normal cells as well as virus-infected cells. Furthermore, elucidation of the actions of IFN at the molecular level is of importance in view of potential applications of interferon in the clinic.
National Institute of Allergy and Infectious Diseases
CFDA Code
856
DUNS Number
094878394
UEI
G9QBQDH39DF4
Project Start Date
01-May-1978
Project End Date
31-March-2010
Budget Start Date
01-July-2005
Budget End Date
31-March-2006
Project Funding Information for 2005
Total Funding
$274,413
Direct Costs
$191,250
Indirect Costs
$83,163
Year
Funding IC
FY Total Cost by IC
2005
National Institute of Allergy and Infectious Diseases
$274,413
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 2R01AI012520-30
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 2R01AI012520-30
Patents
No Patents information available for 2R01AI012520-30
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 2R01AI012520-30
Clinical Studies
No Clinical Studies information available for 2R01AI012520-30
News and More
Related News Releases
No news release information available for 2R01AI012520-30
History
No Historical information available for 2R01AI012520-30
Similar Projects
No Similar Projects information available for 2R01AI012520-30